PROFESSIONAL EDITION

The largest community of pharma leaders

DiosCURE to Develop Highly Specific Single-Chain Antibodies Against SARS-CoV-2, Lead Candidates Described in Science Publication

BONN, Germany–(BUSINESS WIRE)– #COVID19–DiosCURE Therapeutics SE announced a publication in Science describing its core technology of multivalent single-chain antibodies with a unique molecular mode-of-action to inactivate SARS-CoV-2 virions. An international team led by scientists at the University of Bonn developed and characterized the lead candidates, which are exclusively licensed by DiosCURE. “This global pandemic requires an arsenal of therapeutic and preventative tools and our lead candidates w

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles